PE52299A1 - Bencenosulfonamidas de tiazol como agonistas de b3 para el tratamiento de la diabetes y la obesidad - Google Patents

Bencenosulfonamidas de tiazol como agonistas de b3 para el tratamiento de la diabetes y la obesidad

Info

Publication number
PE52299A1
PE52299A1 PE1998000064A PE00006498A PE52299A1 PE 52299 A1 PE52299 A1 PE 52299A1 PE 1998000064 A PE1998000064 A PE 1998000064A PE 00006498 A PE00006498 A PE 00006498A PE 52299 A1 PE52299 A1 PE 52299A1
Authority
PE
Peru
Prior art keywords
obesity
diabetes
treatment
halogen
alkyl
Prior art date
Application number
PE1998000064A
Other languages
English (en)
Inventor
Robert J Mathvink
Ann E Weber
Emma R Parmee
Samuel Tolman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE52299A1 publication Critical patent/PE52299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE X ES UN ENLACE, ALQUILENO C1-C3 QUE PUEDE CONTENER UN OXIGENO Y OPCIONALMENTE SUSTITUIDO CON METILO HALOGENO, m ES 0-5; "A" ES FENILO, HETEROCICLO DE 5-6 MIEMBROS CON 1-4 O o S o N, BENCENO UNIDO A UN CARBOCICLO C5-C10, ENTRE OTROS; R1 ES ALQUILO C1-C10 SUSTITUIDO CON OH, HALOGENO, CN, QR2, Q`COR3, ENTRE OTROS; R2 ES H, ALQUILO C1-C10 SUSTITUIDO CON HASTA 5 GRUPOS SELECCIONADOS DE OH, HALOGENO, CO2R4, ENTRE OTROS; R3 ES R2, NR2R2; R4 ES H, ALQUILO C1-C10; "Q" ES NR2, O, S(O)n, n ES 0-2; Q' ES NR2, O, UN ENLACE. UN COMPUESTO PREFERIDO ES: N[4-[2-[[2-HIDROXI-2-(3-PIRIDINIL)ETIL]AMINO]ETIL]FENIL]-4-[4-2-NAFTILMETIL)TIAZOL-2-IL]BENCENOSULFONAMIDA; EL COMPUESTO DE FORMULA (I) PUEDE SER UTIL EN EL TRATAMIENTO DE DIABETES, OBESIDAD, BAJAR LOS NIVELES DE TRIGLICERIDOS, COLESTEROL, ELEVAR HDL, DISMINUIR LA MOTILIDAD INTESTINAL, DISMINUIR LA INFLAMACION NEUROGENICA DE LAS VIAS RESPIRATORIAS
PE1998000064A 1997-01-28 1998-01-28 Bencenosulfonamidas de tiazol como agonistas de b3 para el tratamiento de la diabetes y la obesidad PE52299A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity

Publications (1)

Publication Number Publication Date
PE52299A1 true PE52299A1 (es) 1999-05-26

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000064A PE52299A1 (es) 1997-01-28 1998-01-28 Bencenosulfonamidas de tiazol como agonistas de b3 para el tratamiento de la diabetes y la obesidad

Country Status (22)

Country Link
EP (1) EP0968209A1 (es)
JP (1) JP2001509166A (es)
KR (1) KR20000070568A (es)
CN (1) CN1251099A (es)
AR (1) AR011092A1 (es)
AU (1) AU728812B2 (es)
BG (1) BG103686A (es)
BR (1) BR9807096A (es)
CA (1) CA2278739A1 (es)
EA (1) EA199900692A1 (es)
EE (1) EE9900328A (es)
HR (1) HRP980044A2 (es)
HU (1) HUP0002053A3 (es)
ID (1) ID22273A (es)
IL (1) IL131130A0 (es)
IS (1) IS5131A (es)
NO (1) NO993646L (es)
PE (1) PE52299A1 (es)
PL (1) PL334833A1 (es)
SK (1) SK100099A3 (es)
TR (1) TR199902442T2 (es)
WO (1) WO1998032753A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
TR200401359T4 (tr) 2000-03-31 2004-08-23 Pfizer Products Inc. İkame edilmiş piridinlerin hazırlanmasına yönelik işlem
JP4988128B2 (ja) * 2000-07-13 2012-08-01 イーライ リリー アンド カンパニー β３アドレナリン作動性アゴニスト
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
CA2421594A1 (en) 2000-11-10 2002-05-16 John Arnold Werner 3-substituted oxindole beta 3 agonists
AU2002221080A1 (en) * 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
ES2255621T3 (es) * 2001-06-22 2006-07-01 MERCK & CO., INC. Inhibidores de tirosina quinasa.
DE60211199T2 (de) 2001-08-14 2007-02-01 Eli Lilly And Co., Indianapolis 3-substituierte oxindol-beta-3-agonisten
ES2272749T3 (es) 2001-08-14 2007-05-01 Eli Lilly And Company Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
CA2463441A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
JP2005518357A (ja) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ３アドレナリンアゴニスト
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2006132196A1 (ja) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
PE20070458A1 (es) 2005-09-14 2007-07-05 Takeda Pharmaceutical Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP1937264B1 (en) * 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BR9807096A (pt) 2000-04-18
WO1998032753A1 (en) 1998-07-30
IS5131A (is) 1999-07-23
HUP0002053A2 (hu) 2001-08-28
ID22273A (id) 1999-09-23
EE9900328A (et) 2000-02-15
NO993646L (no) 1999-09-27
TR199902442T2 (xx) 2000-07-21
CA2278739A1 (en) 1998-07-30
AR011092A1 (es) 2000-08-02
PL334833A1 (en) 2000-03-27
EA199900692A1 (ru) 2000-02-28
HRP980044A2 (en) 1998-10-31
HUP0002053A3 (en) 2001-09-28
JP2001509166A (ja) 2001-07-10
AU6038498A (en) 1998-08-18
BG103686A (bg) 2000-06-30
NO993646D0 (no) 1999-07-27
AU728812B2 (en) 2001-01-18
EP0968209A1 (en) 2000-01-05
CN1251099A (zh) 2000-04-19
IL131130A0 (en) 2001-01-28
KR20000070568A (ko) 2000-11-25
SK100099A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
PE52299A1 (es) Bencenosulfonamidas de tiazol como agonistas de b3 para el tratamiento de la diabetes y la obesidad
PE20020858A1 (es) Indanil aminas aciladas
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
PE20020870A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
PE20060305A1 (es) Compuestos de morfolina como inhibidores de la recaptacion de monoaminas
PE20080251A1 (es) Usos de inhibidores de dpp iv
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
AR035631A1 (es) Compuestos quimicos
PE20060949A1 (es) Derivados fusionados de pirazol como agonistas del receptor de niacina
MXPA03000308A (es) Agonistas beta3 adrenergicos.
PE20081493A1 (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
PE20020540A1 (es) Derivados del acido benzo pirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
NO20052914L (no) Terapeutiske forbindelser
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
AR056175A1 (es) Compuestos de cromano como antagonistas de 5-ht1b
DE602004006869D1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit

Legal Events

Date Code Title Description
FC Refusal